Phase III Trial for new Mesothelioma Treatment Underway

MolMed S.p.A., a biological research firm based in Milan, Italy, stated that they have begun Phase III trials on their new mesothelioma drug. Scientists recently concluded Phase II trials of the drug, called NGR-hTNF, on patients suffering from the disease, which affects the soft tissue surrounding the lungs. Treatment choices for the disease currently do not provide patients with a cure, but act as a method to ease pain and suffering while attempting to reduce and manage tumors.